IL323552A - פוליפפטידים קושרי- gnrhושימושים בהם - Google Patents

פוליפפטידים קושרי- gnrhושימושים בהם

Info

Publication number
IL323552A
IL323552A IL323552A IL32355225A IL323552A IL 323552 A IL323552 A IL 323552A IL 323552 A IL323552 A IL 323552A IL 32355225 A IL32355225 A IL 32355225A IL 323552 A IL323552 A IL 323552A
Authority
IL
Israel
Prior art keywords
gnrh
binding polypeptides
polypeptides
binding
Prior art date
Application number
IL323552A
Other languages
English (en)
Original Assignee
272Bio Ltd
Bioaz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 272Bio Ltd, Bioaz filed Critical 272Bio Ltd
Publication of IL323552A publication Critical patent/IL323552A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL323552A 2023-03-30 2025-09-25 פוליפפטידים קושרי- gnrhושימושים בהם IL323552A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23305451 2023-03-30
PCT/EP2024/058811 WO2024200846A1 (en) 2023-03-30 2024-03-29 Gnrh-binding polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
IL323552A true IL323552A (he) 2025-11-01

Family

ID=86383075

Family Applications (1)

Application Number Title Priority Date Filing Date
IL323552A IL323552A (he) 2023-03-30 2025-09-25 פוליפפטידים קושרי- gnrhושימושים בהם

Country Status (3)

Country Link
AU (1) AU2024245676A1 (he)
IL (1) IL323552A (he)
WO (1) WO2024200846A1 (he)

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879112A (en) * 1984-02-07 1989-11-07 University Of Saskatchewan Monoclonal antibodies agaisnt GnRH
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
DE69330523T4 (de) 1992-08-21 2012-08-23 Vrije Universiteit Brussel Immunoglobuline ohne leichte ketten
ATE341638T1 (de) 1993-02-22 2006-10-15 Univ Rockefeller Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
JP5133494B2 (ja) 2001-08-10 2013-01-30 アバディーン ユニバーシティ 抗原結合ドメイン
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP2008511286A (ja) 2004-06-02 2008-04-17 ダイアテック・ピーティワイ・リミテッド サメ類のＩｇＮＡＲドメインに基づく結合成分
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2014120975A1 (en) 2013-02-01 2014-08-07 California Institute Of Technology Antibody-mediated immunocontraception
CN104558174A (zh) * 2015-01-29 2015-04-29 东南大学 一种针对睾酮的特异性纳米抗体及其应用

Also Published As

Publication number Publication date
AU2024245676A1 (en) 2025-10-09
WO2024200846A1 (en) 2024-10-03

Similar Documents

Publication Publication Date Title
IL304469A (he) חלבוני tnpb הניתנים להנדסה מחדש ושימושיהם
IL284633A (he) פוליפפטידים המכילים פפטידי il-2 ששונו ושימושים בהם
AU2022209849A9 (en) Reprogrammable tnpb polypeptides and use thereof
IL287781A (he) פוליפפטידים נקשרי-12a clec ושימושים בהם
GB202006376D0 (en) Recombinant sars-cov-2 polypeptides and uses
IL287782A (he) פוליפפטידים נקשרי-33cd ושימושים בהם
GB2603645B (en) Polypeptides having anti-senescent effects and uses thereof
GB202011652D0 (en) Polypeptide panels and uses thereof
IL321623A (he) הטרוציקלים ושימושים בהם
IL309562A (he) פוליפפטידים רגנרטיביים ושימושים בהם
GB202109082D0 (en) Polypeptides and uses thereof
GB202012804D0 (en) Agrin polypeptide and uses thereof
EP4326340A4 (en) MODIFIED POLYPEPTIDES AND THEIR USES
CA3267375A1 (en) SYNTHETIC POLYPEPTIDES AND THEIR USES
EP4081235A4 (en) HEPARIN-ASSOCIATED POLYPEPTIDES AND THEIR USE
IL304183A (he) פוליפפטידים וריאנט אקטינוהיבין ושיטות קשורות
IL309885A (he) פוליפפטידים משטח-אלפא ושימושם
CA3251817A1 (en) ALBUMINE-BINDING POLYPEPTIDES AND THEIR USES
IL323552A (he) פוליפפטידים קושרי- gnrhושימושים בהם
IL315757A (he) פוליפפטידים כימריים משופרים ושימושים בהם
IL311185A (he) חלבונים קושרי mog ושימושים בהם
GB202018733D0 (en) Polypeptides and uses thereof
GB202019817D0 (en) Ligand-binding polypeptides and uses thereof
HK40115119A (en) Lilrb polypeptides and uses thereof
HK40109989A (en) Nkp46-binding polypeptides and uses thereof